Changeflow GovPing Legislation NICE Amendment Regulations 2026: Secretary of S...
Priority review Rule Amended Final

NICE Amendment Regulations 2026: Secretary of State Cost-Effectiveness Threshold Power

Favicon for www.legislation.gov.uk UK New Legislation
Published March 24th, 2026
Detected March 4th, 2026
Email

Summary

The UK Secretary of State has issued the National Institute for Health and Care Excellence (Amendment) Regulations 2026, granting the Secretary of State the power to direct NICE on applicable cost-effectiveness thresholds for health technologies. These regulations amend existing 2013 regulations and come into force on March 24, 2026.

What changed

The National Institute for Health and Care Excellence (Amendment) Regulations 2026 introduce a new power for the Secretary of State to direct the National Institute for Health and Care Excellence (NICE) regarding the cost-effectiveness thresholds used in health technology appraisals. This amendment specifically targets regulations governing technology appraisals and highly specialised technology recommendations, allowing the Secretary of State to set or modify these thresholds. The regulations also amend existing consultation requirements, relieving NICE of its obligation to consult on procedural changes necessary to implement a direction from the Secretary of State.

These regulations will have a direct impact on pharmaceutical and medical device manufacturers seeking approval for new health technologies in England and Wales. Companies should be aware that NICE's evaluation criteria for cost-effectiveness may now be subject to direct intervention by the Secretary of State, potentially altering the landscape for market access. While the regulations come into force on March 24, 2026, the specific impact will depend on any future directions issued by the Secretary of State. No immediate compliance actions are required beyond monitoring future NICE guidance or directives related to cost-effectiveness thresholds.

What to do next

  1. Monitor NICE guidance and directives for any changes to cost-effectiveness thresholds.
  2. Assess the impact of potential Secretary of State directions on the appraisal process for new health technologies.

Source document (simplified)

Status:

This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Statutory Instruments

2026 No. 202

HEALTH AND SOCIAL CARE, ENGLAND AND WALES

The National Institute for Health and Care Excellence (Amendment) Regulations 2026

Made

2nd March 2026

Laid before Parliament

3rd March 2026

Coming into force

24th March 2026

The Secretary of State makes these Regulations in exercise of the powers conferred by sections 237(1) and (2) and 304(9) and (10) of the Health and Social Care Act 2012(1).

Citation, commencement and extent

  1. —(1) These Regulations may be cited as the National Institute for Health and Care Excellence (Amendment) Regulations 2026 and comes into force on 24th March 2026.

(2) These Regulations extend to England and Wales.

Amendment of the National Institute for Health and Care Excellence (Constitution and Functions) and NHS England (Information Functions) Regulations 2013

  1. The National Institute for Health and Care Excellence (Constitution and Functions) and NHS England (Information Functions) Regulations 2013(2) are amended as follows.

Amendment to regulation 7

  1. —(1) Regulation 7 (NICE technology appraisal recommendations) is amended as follows.

(2) After paragraph (1) insert—

“ (1A) The Secretary of State may direct NICE as to the applicable cost-effectiveness threshold to apply to a health technology undergoing appraisal. ”.

(3) In paragraph (9) before “NICE must” insert “Subject to paragraph (9A),”.

(4) After paragraph (9) insert—

“ (9A) The obligation to consult does not apply to a change to procedures that are necessary to give effect to a direction given by the Secretary of State made under paragraph (1A). ”.

(5) After paragraph (14) insert—

“ (15) In this regulation and regulation 8—

“ cost-effectiveness threshold ” means the value, whether expressed as a single figure or a range, against which NICE evaluates the cost-effectiveness or value for money of a health technology or highly specialised health technology. ”.

Amendment to regulation 8

  1. —(1) Regulation 8 (NICE highly specialised technology recommendations) is amended as follows.

(2) After paragraph (1) insert—

“ (1A) The Secretary of State may direct NICE as to the applicable cost-effectiveness threshold to apply to a highly specialised health technology undergoing appraisal. ”.

(3) In paragraph (8) before “NICE must” insert “Subject to paragraph (8A),”.

(4) After paragraph (8) insert—

“ (8A) The obligation to consult does not apply to a change to procedures necessary to give effect to a direction given by the Secretary of State made under paragraph (1A). ”.

Signed by the authority of the Secretary of State for Health and Social Care.

Zubir Ahmed

Parliamentary Under Secretary of State

Department of Health and Social Care

2nd March 2026

Explanatory Note

(This note is not part of the Regulations)

These Regulations amend the National Institute for Health and Care Excellence (Constitution and Functions) and NHS England (Functions) Regulations 2013 (S.I. 2013/259) (“ 2013 Regulations ”). The purpose of these amendments is to introduce a power for the Secretary of State to direct the National Institute of Health and Care Excellence (“ NICE ”) with regard to the cost-effectiveness threshold NICE is to apply to health technologies when carrying out technology appraisals under regulation 7 of the 2013 Regulations or appraising highly specialised health technologies under regulation 8 of the 2013 Regulations.

Regulation 3 amends regulation 7 of the 2013 Regulations to introduce a power of direction to specify the cost-effectiveness threshold NICE must apply to technology appraisals it carries out. Regulations 3(3) and (4) introduce amendments that relieve NICE of its obligation to consult under regulation 7(9) of the 2013 Regulations where relevant changes to procedures are necessary to give effect to a direction concerning the cost-effectiveness threshold.

Regulation 4 amends regulation 8 of the 2013 Regulations to introduce a power of direction to specify the cost-effectiveness threshold NICE must apply to highly specialised health technology appraisals it carries out. Regulations 4(3) and (4) introduce amendments that relieve NICE of its obligation to consult under regulation 8(8) of the 2013 Regulations where the relevant changes to procedures are necessary to give effect to a direction concerning the cost-effectiveness threshold.

An impact assessment relating to this instrument has been prepared and copies can be obtained from the Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU and is available on the www.legislation.gov.uk website.

(1) 2012 c. 7. Sections 237(1) and (2) were amended by the Health and Care Act 2022 (c. 31) section 1 and Schedule 1 paragraph 1. There are no relevant amendments to section 304.

(2) S.I. 2013/259. The relevant amending instruments are S.I. 2022/634 and 2023/98.

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
Various UK Agencies
Published
March 24th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Geographic scope
England and Wales

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
Pharmaceuticals Health Technology Assessment

Get Legislation alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when UK New Legislation publishes new changes.

Free. Unsubscribe anytime.